290 likes | 409 Views
Wednesday Case Conference. Yvonne L. Carter, MD 04 June 2008. HPI. 87yo CM with 3d h/o right facial swelling and rash Started as a little spot on the forehead Spread to involve entire right face, causing him to be unable to open his right eye Denies burning/itching/pain
E N D
Wednesday Case Conference Yvonne L. Carter, MD 04 June 2008
HPI • 87yo CM with 3d h/o right facial swelling and rash • Started as a little spot on the forehead • Spread to involve entire right face, causing him to be unable to open his right eye • Denies burning/itching/pain • Denies any vesicles or pustules • Skin feels very sensitive • Denies HA, ear pain, vision loss, neck stiffness
Osteoporosis HTN CAD, s/p MI 2005 GERD Hypothyroidism IBS Diverticulosis Raynaud’s Iron Def. Anemia BPH Anxiety Allergic Rhinitis Basal Cell CA, 1999 Peripheral Neuropathy PMH
SocHx Lives with wife No sick contacts No tobacco/Etoh No travel No pets FamHx Mom – pancreatic cancer Dad – CAD, MI
Allergies Penicillin Bactrim Medications Aspirin Tylenol Ca/Vit D MVI Fosamax Lovastatin Synthroid Vesicare
Physical Examination • T 36.3, P 54, BP 112/65, R 20, 97% RA • Elderly, thin, kyphotic • Neck supple, OP clear, No LAD • RRR, Nrml S1S2, No m/g/r • Lungs CTA b/l • Abd benign • Skin: Right scalp with a few flaccid vesicles, some areas of denuded skin, and some scab formation. Erythema and edema surrounding right eye
Lab Data 9.5 130 99 32 2.3 81 4.5 25 1.54 3.9 11.0 3.7 187 33.3
Imaging • Maxillofacial CT: • Soft tissue swelling seen about the right orbit anterior to the globe, likely representing preseptal cellulitis
Hospital Course • Received Vancomycin in ED • Started on Clindamycin upon admit • Lesions swabbed for HSV/VZV • Positive for VZV • Started on IV Acyclovir with improvement • Discharged on Valacyclovir and Clindamycin
VZV (Zoster) • Human pathogen that infects 98% of the population in the US • Enters sensory nerves in mucocutaneous sites and travels through retrograde axonal transport to the sensory dorsal root ganglia adjacent to the spinal cord where the virus establishes permanent latency in neuronal cell bodies • Latent VZV present in 1-7% of sensory ganglion neurons, with <10 genomic copies per cell infected
Headache Photophobia Malaise Abnormal skin sensations of varying severity Unilateral vesicular rash distributed across closely overlapping dermatomes Thoracic, cervical, opthalmic dermatomes most common Clinical Features
Rash • Initially erythematous and maculopapular but progresses to form coalescing clusters of clear vesicles containing high concentrations of VZV • Vesicles evolve through pustular, ulcer, and crust stages • Usually lasts 7-10 days, with complete healing in 2-4 weeks
Complications • Post-herpetic neuralgia (PHN) • Herpes Zoster opthalmicus (HZO) • 10-25% of affected patients • Occurs when reactivation involves the nasociliary branch of the trigeminal nerve, sometimes preceeded by presence of vesicles on the nose (Hutchinson sign) • Ramsay Hunt Syndrome
Keratitis, leading to corneal ulceration Conjunctivitis Uveitis Episcleritis and scleritis Retinitis Choroiditis Optic Neuritis Lid Retraction Ptosis Glaucoma Extraocular muscle palsies Other Ocular Complications
Prevention of Herpes Zoster CDC released MMWR May 15, 2008, with Recommendations of the Advisory Committee on Immunization Practices
Recommendations for Use of Zoster Vaccine • Routine Vaccination of Persons Aged > 60 • Persons who report a previous episode of zoster and persons with chronic medical conditions can be vaccinated unless those conditions are contraindications • Not indicated to treat acute zoster, to prevent PHN, or treat ongoing PHN • It is NOT necessary to ask about history of varicella or conduct serologic testing for immunity prior to vaccination
Zoster Vaccination • Offers an opportunity to decrease the burden of disease and its complications among persons with high level of risk • In placebo-controlled clinical trial, vaccination reduced overall incidence of zoster by 51.3%, and reduced incidence of PHN by 66.5% Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271--84.
Zoster Vaccine • Zostavax® (Merck & Co., Inc) liscensed for use in US In 2006 • Live, attenuated VZV (Oka strain - same strain used in varicella vaccines) • Each dose is 0.65ml, and contains a minimum of 4.29 log of Oka strain of VZV • 14x more potent than Varivax • Also contains additional VZV antigenic component from nonviable Oka VZV • Administered as single subcutaneous dose in the deltoid region of the upper arm
Vaccine NOT licensed for: • Persons <60 yrs old • Persons who have received varicella vaccine
Special Groups • Persons with a History of Zoster • Persons Anticipating Immunosuppression • Give at least 14 days prior to use of immunosuppressants • Persons Receiving Antiviral Medications • Acyclovir, Famciclovir, and Valacyclovir should be held for 24hrs prior to vaccination • Persons Receiving Blood Products • Nursing Mothers • Vaccine not secreted in breast milk • Moderate to Severe Illness
Contraindications • Allergy to Vaccine Components (gelatin, neomycin) • Immunocompromised Patients • Pregnancy • Having a pregnant household member is not a contraindication to vaccination